The molecular basis of hepatitis B e antigen (HBeAg)-negative infections

Journal of Viral Hepatitis

Volumn 4, Issue 1, 1997, Pages 1-8

  Miyakawa, Y ^a   Okamoto, H ^b   Mayumi, M ^b  

^a Miyakawa Memorial Research Foundation   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Fulminant hepatitis; HBeAg; Hepatitis B virus; Promoter regions; Transcription; Translation

Indexed keywords

HEPATITIS B(E) ANTIGEN;

BLOOD; GENETICS; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; LIVER; METABOLISM; PATHOLOGY; PHENOTYPE; POINT MUTATION; PROMOTER REGION; REVIEW; STOP CODON; VIROLOGY;

CODON, TERMINATOR; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER; PHENOTYPE; POINT MUTATION; PROMOTER REGIONS (GENETICS);

EID: 0030636375     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1997.00101.x     Document Type: Review

References (64)

1. Magnius LO, Espmark JA. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972; 109: 1017-1021.
2. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y, Mayumi M. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294: 746-749.
3. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1: 695-698.
4. Takahashi K, Imai M, Tsuda F, Takahashi T, Miyakawa Y, Mayumi M. Association of Dane particles with e antigen in the serum of asymptomatic carriers of hepatitis B surface antigen. J Immunol 1976; 117: 102-105.
5. Imai M, Tachibana FC, Moritsugu Y, Miyakawa Y, Mayumi M. Hepatitis B antigen-associated deoxyribonucleic acid polymerase activity and e antigen/anti-e system. Infect Immun 1976; 14: 631-635.
6. Takahashi K, Imai M, Miyakawa Y, Iwakiri S, Mayumi M. Duality of hepatitis B e antigen in serum of persons infected with hepatitis B virus: evidence for the nonidentity of e antigen with immunoglobulins. Proc Natl Acad Sci USA 1978; 75: 1952-1956.
7. Neurath AR, Strick N. Host specificity of a serum marker for hepatitis B: evidence that 'e antigen' has the properties of an immunoglobulin. Proc Natl Acad Sci USA 1977; 74: 1702-1706.
8. Takahashi K, Akahane Y, Gotanda T et al. Demonstration of hepatitis B e antigen in the core of Dane particles. J Immunol 1979; 122: 275-279.
9. MacKay P, Lees J, Murray K. The conversion of hepatitis B core antigen synthesized in E. coli into e antigen. J Med Virol 1981; 8: 237-243.
10. Tiollais P, Charnay P, Vyas GN. Biology of hepatitis B virus. Science 1981; 213: 406-411.
11. Bruss V, Gerlich WH. Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein. Virology 1988; 163: 268-275.
12. Garcia PD, Ou JH, Rutter WJ, Walter P. Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. J Cell Biol 1988; 106: 1093-1104.
13. Takahashi K, Machida A, Funatsu G et al. Immunochemical structure of hepatitis B e antigen in the serum. J Immunol 1983; 130: 2903-2907.
14. Hsu HY, Chang MH, Lee CY et al. Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis 1995; 171: 776-781.
15. Takahashi K, Kishimoto S, Ohori K et al. Molecular heterogeneity of e antigen polypeptides in sera from carriers of hepatitis B virus. J Immunol 1991; 147: 3156-3160.
16. Campillo ML, Quiroga JA, Bartolome J, Moraleda G, Castillo I, Carreno V. Protein composition of the hepatitis B virus e antigen in the natural course of disease and following interferon therapy. J Clin Microbiol 1992; 30: 1256-1261.
17. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591.
18. Yotsumoto S, Kojima M, Shoji I, Yamamoto K, Okamoto H, Mishiro S. Fulminant hepatitis related to transmission of hepatitis B variants with precore mutations between spouses. Hepatology 1992; 16: 31-35.
19. Okamoto H, Yotsumoto S, Akahane Y et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298-1303.
20. Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrison TJ. Precore and core mutations in HBV from individuals in India with chronic infection. J Med Virol 1995; 45: 321-325.
21. Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69: 2575-2583.
22. Naumann H, Schaefer S, Yoshida CF, Gaspar AM, Repp R, Gerlich WH. Identification of a new hepatitis B virus (HBV) genotype from Brazil that expresses HBV surface antigen subtype adw4. J Gen Virol 1993; 74: 1627-1632.
23. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489-503.
24. Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol 1987; 671: 3030-3034.
25. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990; 9: 3389-3396.
26. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993; 67: 5402-5410.
27. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 1994; 91: 4077-4081.
28. Yuh CH, Chang YL, Ting LP. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol 1992; 66: 4073-4084.
29. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102-8110.
30. Corden J, Wasylyk B, Buchwalder A, Sassone CP, Kedinger C, Chambon P. Promoter sequences of eukaryotic protein-coding genes. Science 1980; 209: 1406-1414.
31. Wasylyk B, Chambon P. A T to A base substitution and small deletions in the conalbumin TATA box drastically decrease specific in vitro trranscription. Nucl Acids Res 1981; 9: 1813-1824.
32. White RJ, Jackson SP. The TATA-binding protein: a central role in transcription by RNA polymerases I, II and III. Trends Genet 1992; 8: 284-288.
33. Sato S, Suzuki K, Akahane Y et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122: 241-248.
34. Mondelli MU, Bortolotti F, Pontisso P et al. Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. Clin Exp Immunol 1987; 68: 242-250.
35. Bertoletti A, Ferrari C, Fiaccadori F et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88: 10445-10449.
36. Trepo CG, Robert D, Motin J, Trepo D, Sepetjian M, Prince AM. Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance. Gut 1976; 17: 10-13.
37. Woolf IL, El SN, Cullens H et al. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J 1976; 2: 669-671.
38. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992; 37: 1253-1259.
39. Karayiannis P, Alexopoulou A, Hadziyannis S et al. Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: importance of host factors. Hepatology 1995; 22: 1628-1634.
40. Oren I, Hershow RC, Ben PE et al. A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Med 1989; 110: 691-698.
41. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben PE. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324: 1705-1709.
42. Tanaka S, Yoshiba M, Iino S et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int 1995; 48: 1972-1978.
43. Gimson AE, Tedder RS, White YS, Eddleston AL, Williams R. Serological markers in fulminant hepatitis B. Gut 1983; 24: 615-617.
44. Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100: 1087-1094.
45. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324: 1699-1704.
46. Kojima M, Shimizu M, Tsuchimoch T et al. Posttransfusion fulminant hepatitis B associated with precore-defective HBV mutants. Vox Sang 1991; 60: 34-39.
47. Terazawa S, Kojima M, Yamanaka T et al. Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen. Pediatr Res 1991; 29: 5-9.
48. Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology 1993; 105: 1173-1178.
49. Feray C, Gigou M, Samuel D, Bernuau J, Bismuth H, Brechot C. Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. J Hepatol 1993; 18: 119-122.
50. Laskus T, Rakela J, Nowicki MJ, Persing DH. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 1995; 109: 1618-1623.
51. Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology 1994; 19: 836-840.
52. Alter HJ, Bradley DW. Non-A, non-B hepatitis unrelated to the hepatitis C virus (non-ABC). Semin Liver Dis 1995; 15: 110-120.
53. Simons JN, Leary TP, Dawson GJ et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995; 1: 564-569.
54. Linnen J, Wages J, Zhang-Keck ZY et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271: 505-508.
55. Wright TL, Etiology of fulminant hepatic failure: is another virus involved? Gastroenterology 1993; 104: 640-643.
56. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 1995; 346: 1131-1132.
57. Tameda Y, Kosaka Y, Tagawa S et al. Infection with GB virus C (GBV-C) in patients with fulminant hepatitis. J Hepatol 1996; in press.
58. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87: 6599-6603.
59. Brunetto MR, Giarin MM, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88: 4186-4190.
60. Arakawa K, Tsuda F, Takahashi K et al. Maternofetal transmission of IgG-bound hepatitis B e antigen. Pediatr Res 1982; 16: 247-250.
61. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993; 67: 3756-3762.
62. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994; 68: 1651-1659.
63. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
64. Miyakawa Y, Mayumi M. Hepatitis B e antigen and antibody (HBeAg/anti-HBe). In: Grety RH, ed. Hepatitis B. Orlando: Academic Press, 1985: 47-76.